Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Hodgkin Disease 1

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × rhoA GTP-Binding Protein × Clear all
NCT05218096 2025-01-09

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 2 Terminated
70 enrolled 14 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡